Cerus Corporation Announces Presentation of Study Results with INTERCEPT-treated COVID-19 Convalescent Plasma at the American Society of Hematology Annual Meeting

Rhea-AI Summary

Cerus Corporation (Nasdaq: CERS) announced a clinical study on the efficacy of INTERCEPT-treated COVID-19 convalescent plasma, presented by Dr. Nina Khanna at the American Society of Hematology Annual Meeting on December 5, 2020. The study, involving 15 patients treated with INTERCEPT CCP, showed a 93.3% survival rate at day 28, compared to 20% in the control group. Conducted in collaboration with various research institutions, the findings highlight the potential of INTERCEPT technology in combating COVID-19 and improving patient outcomes.

Positive

• 93.3% survival rate for INTERCEPT-treated CCP patients at day 28.
• Successful collaboration with University Hospital of Basel and other research teams.
• Demonstrated potential for INTERCEPT technology to enhance treatment efficacy during epidemics.

Negative

• None.

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced the oral presentation of a clinical study: “Efficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for Patients with Moderate to Severe Acute COVID-19: A Case Matched Control Study,” presented by Dr. Nina Khanna of the University Hospital of Basel, Switzerland, at the American Society of Hematology Annual Meeting, on Saturday, December 5, 2020, at 2:45 pm/EST. This presentation reviews data on the efficacy of INTERCEPT-treated COVID-19 convalescent plasma (CCP) to treat COVID-19 pneumonia patients.

Initiated in March 2020, the study was conducted in collaboration with Cerus and Vitalant Research Institute, San Francisco; Vaccine Research and Development Laboratory, University of California, Irvine, CA; and Enable Biosciences, San Francisco, CA.

The study of hospitalized patients with documented COVID-19 pneumonia enrolled 15 subjects who received INTERCEPT-treated CCP and 30 matched controls who received standard therapy without CCP transfusion. Of the 15 patients treated with INTERCEPT-treated CCP, 14 (93.3%) responded and were alive at study day 28. Three patients were severely immune-compromised. Among the 30 matched control patients, 6 (20%) died by study day 28.

“The study summarizes the successful collaboration with the University Hospital of Basel, Cerus, and the other California-based research teams, generating important data to define CCP virus-neutralizing efficacy at the onset of the COVID-19 pandemic. We are encouraged by the patients’ responses to INTERCEPT-treated CCP and the preservation of neutralizing antibodies in INTERCEPT-treated CCP. The data from this study demonstrate the ability to identify effective CCP during epidemics that, with pathogen reduction to decrease the risk of transfusion-transmitted disease, can be rapidly introduced into routine practice,” said Dr. Laurence Corash, Cerus’ chief scientific officer.

To view the oral presentation on Saturday, December 5, click here: https://ash.confex.com/ash/2020/webprogram/Paper136180.html

About University Hospital of Basel and the Regional Swiss Red Cross Blood Transfusion Center, Basel, Switzerland.

The University Hospital of Basel is a specialized medical research and patient care facility. The Regional Swiss Red Cross Blood Transfusion Center, located in the University Hospital, conducts research studies in transfusion medicine.

About Cerus

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding associated with fibrinogen deficiency, including massive hemorrhage. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.